| Document |
Document Title |
|
WO/2022/131869A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2022/130238A1 |
A new process for the synthesis of amide derivatives of 8-hydroxypenicillanic acid is described, more specifically starting from amide derivatives of the 6-aminopenicillanic nucleus protected as tert-butylcarbamate.
|
|
WO/2022/131757A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2022/133345A1 |
Compounds with KRAS G12C inhibitory activity are disclosed and methods of using the same to treat a cancer comprising a K-Ras G12C mutation. Preferably the compounds fall within formula (I).
|
|
WO/2022/129331A1 |
The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseas...
|
|
WO/2022/133064A1 |
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific irreversible inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions th...
|
|
WO/2022/125849A1 |
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal lobe dementia (FTLD).
|
|
WO/2022/117473A1 |
The present invention relates to heterocyclic compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2022/115400A1 |
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound IA, wherein R1 is described herein. Compound IA can be useful in sy...
|
|
WO/2022/105930A1 |
The present disclosure provides compounds of Formula (I) a pharmaceutically acceptable salt, a stereoisomer, or a tautomer thereof, for use in, e.g. treating a condition, disease or disorder in which increased (e.g., excessive) STING act...
|
|
WO/2022/109573A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and phar...
|
|
WO/2022/108354A1 |
The present invention provides a novel compound, a solvate thereof, a hydrate thereof, a prodrug thereof, an isomer thereof or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an antibiotic composition compri...
|
|
WO/2022/106469A2 |
The present invention provides compounds of formula (I) which are useful in the control of endoparasites, for example heartworms, in warm-blooded animals.
|
|
WO/2022/100717A1 |
Disclosed are a leukocyte classification reagent and kit, a classification method, an erythrocyte analysis reagent and kit, and an analysis method. Both the leukocyte classification reagent and the erythrocyte analysis reagent comprise a...
|
|
WO/2022/100727A1 |
The present invention provides a novel class of imidazothiazole compounds as ATX (Autotaxin) inhibitors, a pharmaceutical composition comprising the compound, and a use of the compound and the composition to treat a mammal suffering from...
|
|
WO/2022/099659A1 |
Provided are a leukocyte classification reagent, reagent kit, and classification method, and an erythrocyte analysis reagent, reagent kit, and analysis method. Each of the leukocyte sorting reagent and the erythrocyte analysis reagent co...
|
|
WO/2022/089296A1 |
Disclosed are a thienopyrimidine compound, a pharmaceutical composition comprising same, and an application thereof. The thienopyrimidine compound has a structure represented by formula I. The compound interferes with the interaction bet...
|
|
WO/2022/093856A1 |
The present disclosure provides compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses and methods of treating certain ...
|
|
WO/2022/078971A1 |
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregat...
|
|
WO/2022/078350A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating cancers and related conditions.
|
|
WO/2022/079290A2 |
The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target pro...
|
|
WO/2022/076796A1 |
The present disclosure provides novel macrocyclic peptides which inhibit the PD- 1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
|
|
WO/2022/076794A1 |
The present disclosure provides novel macrocyclic peptides which inhibit the PD- 1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
|
|
WO/2022/076629A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions, containing at least one such modulator, methods of treatment of cystic fibrosis usi...
|
|
WO/2022/036060A9 |
Crystalline forms of salts of Compound I are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
|
|
WO/2022/066805A1 |
A compound of Formula (I) is provided: where the variables are defined herein.
|
|
WO/2022/063896A1 |
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and...
|
|
WO/2022/064075A1 |
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as CXCR4 modulators that specifically target the CXCR4 minor pocket, and they ...
|
|
WO/2022/064187A1 |
A compound of formula (I-1), or a pharmaceutically acceptable salt or hydrate thereof, formula (I-1) wherein: ring A is a monocyclic 5, 6, or 7-membered heterocycloalkyl ring optionally substituted by one or more substituents selected fr...
|
|
WO/2022/064459A1 |
The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salts thereof, a composition comprising the compound, methods of using the compound for the treatment of various disorders associated with HPK1, and...
|
|
WO/2022/064429A1 |
The invention provides compounds of Formula (I) for inhibiting glycosidases, pro drugs of the compounds, and pharmaceutical compositions comprising the compounds or prodrugs of the compounds. The invention also provides methods of treati...
|
|
WO/2022/063299A1 |
The present invention relates to a 1,2,4-triazolone derivative serving as a DHODH inhibitor. The present invention specifically relates to a compound shown by general formula (1) and a preparation method therefor, and an application of t...
|
|
WO/2022/060951A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2022/059778A1 |
The present invention provides a compound that has an inhibitory effect on DYRK and is represented by general formula (I) (in the formula, A1, A2, L, R1, and R2 are as described in the specification).
|
|
WO/2022/060836A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2022/060943A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2022/059779A1 |
The invention of the present application provides an amine derivative having a DYRK-inhibiting activity and represented by formula (1) (see the description with respect to A1, A2, L1, L2, X, Z, R1 and R4 in the formula), or a pharmaceuti...
|
|
WO/2022/053660A2 |
The use of an N-heterocyclic compound of the general formula (a) or (b) with the following definitions: X1 being S or O, X2 being S or O and at least one of X1 and X2 being S R2 H or C1-4-alkyl, R3 H or C1-4-alkyl R6 and R7 are hydrogen ...
|
|
WO/2022/055168A1 |
The present invention relates to a pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof and a use thereof. A pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof according to the present invent...
|
|
WO/2022/051567A1 |
The invention provides substituted pyrido[2,3-b]pyrazinones and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.
|
|
WO/2022/051569A1 |
The invention provides substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.
|
|
WO/2022/051568A1 |
The invention provides substituted 4-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.
|
|
WO/2022/051565A1 |
The invention provides substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disor...
|
|
WO/2022/051317A1 |
Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Y that can be used to prepare them where the variable R1 is as defined herein. In particular, provided herein are processes for synthesizi...
|
|
WO/2022/043537A1 |
The present disclosure provides a compound of Formula I which may be used in the diagnosis, treatment and/or prevention of a disease or disorder involving amyloid.
|
|
WO/2022/043491A2 |
Disclosed herein are detectable moieties and detectable conjugates comprising one or more detectable moieties. In some embodiments, the disclosed detectable moieties have a narrow wavelength and are suitable for multiplexing. Also disclo...
|
|
WO/2022/038563A1 |
The present technology is directed to compounds, compositions, and methods related to modulation of MNK. In particular, the present compounds and compositions may be used to treat MNK-mediated disorders and conditions, including, e.g., v...
|
|
WO/2022/028007A1 |
The present disclosure relates to an intermediate for preparing edoxaban free base, a preparation method therefor and an application thereof. The preparation method for the intermediate comprises the following steps: in an organic solven...
|
|
WO/2022/029096A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2022/020550A1 |
The present invention provides compounds of the structural Formula (I) and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combina...
|
